secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2023-09-27T23:59:59+00:00
Accession:  0000886163-23-000071
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ligand appoints Martine Zimmermann to board of directors
--------------------------------------------------------

- Zimmermann appointed on Sept 22, 2023; serves as independent director.
- SVP and Head of Regulatory Affairs and R&D Quality at Ipsen Biopharmaceuticals since Jan 2023.
- Granted RSUs (2,285 shares) and options (11,345 shares at $59.08 strike), vesting over 3 years.
- Also receives cash compensation per company's director compensation policy.
- Board determined Zimmermann independent under Nasdaq rules; no material transactions with company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616323000071/0000886163-23-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616323000071/lgnd-20230922.htm
  HTML page:      https://secwatch.observer/filing/0000886163-23-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer